How sweet it is: Modern treatment approaches for type II diabetes

ANGELA L. GOODHART, PHARMD, BCACP ASSISTANT PROFESSOR OF CLINICAL PHARMACY AND FAMILY MEDICINE WEST VIRGINIA UNIVERSITY ANGELA.GOODHART@HSC.WVU.EDU

DISCLOSURES

I have nothing to disclose concerning possible financial relationships with ineligible companies that may have a direct or indirect interest in the subject matter of this presentation.

LEARNING OBJECTIVES



Review the pharmacokinetics, efficacy, and safety considerations of diabetes medications, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors.



Explain the fundamental concepts of continuous glucose monitor (CGM) technology and interpretation of data.



Assess the evidence supporting CGM use in diabetes.




Discuss the role of pharmacists providing diabetes care within a multidisciplinary team.

THE EVOLUTION OF DIABETES PHARMACOTHERAPY

Safety	 Concern for adverse events Required CV trials 		
Cardiovascular Benefits	 Major Adverse Cardiovascular Events (MACE) Heart Failure 		
Weight Benefits	ObesityOverweight		
Liver Benefits	 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Metabolic Dysfunction-Associated Steatohepatitis (MASH) 		

American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S336. Available from: https://diabetesjournals.org/care/issue/48/Supplement_1. Accessed 2025 Mar 3.


WHAT WE WILL NOT COVER TODAY:







METFORMIN

- Mechanism: decreases hepatic glucose production, improves insulin sensitivity, thought to provide appetite regulation
- FDA indications: diabetes type 2
- Off label: prevention of diabetes type 2; gestational diabetes; polycystic ovarian syndrome, antipsychotic induced weight gain







METFORMIN ADVERSE EFFECTS

- Common side effects:
 - GI: nausea, vomiting, diarrhea, flatulence
- Severe side effects (SAE):
 - Lactic acidosis
 - Vitamin B12 deficiency (monitor every 2-3 years)

Lexicomp. Metformin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

METFORMIN DOSING CONSIDERATIONS

Starting dose 500 mg daily; increase by **500 mg** per day every week as tolerated

Maximum: 2000-2500 mg total daily dose

Extended release better tolerated \rightarrow improved adherence

Counsel to take with food to minimize side effects

Avoid extended release if history of bariatric surgery; immediate release tablets can be cut/crushed

Lexicomp. Metformin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

ADDITIONAL CLINICAL CONSIDERATIONS: METFORMIN

Contraindications:

- GFR < 30 ml/min (can use if GFR 30-44 ml/min if already taking but requires 50% dose reduction)
- Metabolic acidosis including lactic acidosis and diabetic ketoacidosis and associated risk factors (excessive alcohol intake)
- Severe liver disease or heart disease (caution)

Safe in pregnancy

\$ cheap

Lexicomp. Metformin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

Sodium glucose cotransporter –2 inhibitors (SGLT2 inhibitors)

bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin

11

SGLT-2 INHIBITORS

- Agents: bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin
- Mechanism: decreases reabsorption of glucose in the proximal tubules by inhibiting sodiumglucose cotransporter 2 → increased glucose excretion
- FDA indications: Diabetes type 2, chronic kidney disease, heart failure



Lexicomp. Empagliflozin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

ADVERSE EFFECTS


- Commons side effects:
 - Minimal
- Serious side effects:
 - Infections (urinary tract and genitourinary fungal)
 - Acute kidney injury
 - Hypotension/volume depletion
 - Ketoacidosis
 - Amputations?

Lexicomp. Empagliflozin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

AMPUTATION RISK

- Initial BBW with canagliflozin (2017)
 - Specifically toe, foot, and lower leg
- Conflicting data, specific to canagliflozin
 - CANVAS/CANVAS-R → increased risk
 - CREDENCE → no difference
- BBW removed in 2020
 - "risk of amputation...is lower than previously described, particularly when appropriately monitored" (8-26-2020 FDA Drug Safety Communication)

Lexicomp. Canagliflozin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp



SGLT-2 INHIBITORS - RENAL DOSING

Do not initiate	20 ml/min (empagliflozin)		
in dialysis or with GFR less than:	25 ml/min (dapagliflozin)		
	30 ml/min (bexagliflozin, canagliflozin)		
	45 ml/min (ertugliflozin)		

Drugs 79, 219–230 (2019). https://doi.org/10.1007/s40265-019-1057-0

CLINICAL CONSIDERATIONS FOR SGLT-2

Contraindications:

- DM type 1
- Any history of ketoacidosis
- Pregnancy

Euglycemia

• Must be able to maintain adequate PO intake

Weight loss

• Variable, average 1-3 kg

\$\$\$ brand only, expensive

Lexicomp. Canagliflozin. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

Glucagon-like peptide-1 agonists (GLP-1 agonists)

dulaglutide, liraglutide, semaglutide

17

GLP-1 AGONISTS

- Mechanism: GLP-1 is an incretin hormone

 → glucose dependent insulin secretion,
 decreases inappropriate glucagon secretion,
 increases B-cell growth, slows gastric
 emptying, decreases food intake, improves
 insulin sensitivity
- FDA indications: Diabetes type 2, weight management chronic



Lexicomp. Liraglutide. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

ADVERSE EFFECTS

Common side effects

• GI: diarrhea, nausea, vomiting, constipation, abdominal pain

Severe side effects

- Renal: AKI (through dehydration)
- GI: pancreatitis, cholelithiasis, cholecystitis
- Contraindications
- Personal or family history of medullary thyroid cancer or MEN2 syndrome (due to association in rodents)
- Pregnancy
- Pancreatitis (caution)

MEN2-multiple endocrine neoplasia 2

Lexicomp. Liraglutide. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

GLP-1 AGONISTS: DRUG INTERACTIONS

DPP-4 inhibitors

- Pancreatitis risk
- No increased efficacy
- AVOID combination

Insulins/secretagogues

- Hypoglycemia risk
- Use with caution
- Monitor and adjust doses

Lexicomp. Liraglutide. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

Liraglutide (Victoza®, Saxenda®) 2010, 2014

LIRAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES (LEADER)

- Study Design: Multicenter, double-blind, randomized, placebo-controlled trial
- Participants: 9,340 adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk
- Duration: Median follow-up 3.8 years
- Intervention: Liraglutide (up to 1.8 mg daily) vs. placebo
- Primary Endpoint: Composite major adverse cardiovascular events (MACE):
 - Cardiovascular death
 - Nonfatal myocardial infarction (MI)
 - Nonfatal stroke
- Key Findings:
 - Significant reduction in MACE (HR: 0.87, 95% CI: 0.78–0.97, p=0.01)
 - Lower cardiovascular mortality (HR: 0.78, *p*=0.007)
 - No increased risk of severe hypoglycemia or pancreatic adverse events

The New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827

Liraglutide Literature – Weight Loss

- Trials included: 11 RCTs, n=3964 in treatment groups
- Mean age: 43-59 years
- Predominantly female
- Lifestyle: calorie deficit with variable restrictions

Mean Starting Weight	Mean Starting BMI	Mean Starting Waist Circumference	Comorbidities Included	Follow Up Duration
100-105 kg	> 30 kg/m ²	-	DM type 2 in 3 studies, 1 allowed insulin	52 weeks

Liraglutide Outcomes – Weight Loss

% TBWL*	Weight loss*	Percent achieving 5% TBWL*	Percent achieving 10% TBWL*	Percent achieving 15% TBWL*
4.81%	5.3 kg	28.9%	17.3%	9.2%

*Reported as mean difference compared to placebo group

SCALE insulin RCT – majority of patients no longer using insulin at end of the trial

LIRAGLUTIDE SAFETY

Discontinuation significantly higher in liraglutide groups (9.1%)


- Reasons: GI adverse effects
- No difference in severe adverse events

Nausea and vomiting more common in liraglutide group

- Nausea 40%
- Vomiting 16%

Acute pancreatitis < 0.1%

Liraglutide Injection



Clinical considerations for liraglutide

Available as 2 brand names (and now generic) Similar injection technique but different max doses

Dial up pen with ability to self-titrate dose

Need Rx for pen needles!!

www.fda.gov

Semaglutide (Ozempic[®], Wegovy[®]) 2017, 2021

Semaglutide Literature – Weight Loss

- Trials included: 8 RCTs, n=2658 in treatment groups
- Mean age: 46-59.5 years
- Predominantly female
- Lifestyle: most included 500 kcal/d deficit

Mean Starting Weight	Mean Starting BMI	Mean Starting Waist Circumference	Comorbidities Included	Follow Up Duration
86.9-113.2 kg	32-39.9kg/m²	103.8-119 cm	4 excluded DM, 3 mixed, 1 required DM	52-72 weeks

Semaglutide Outcomes – Weight Loss

% TBWL*	Weight loss*	Percent achieving 5% TBWL*	Percent achieving 10% TBWL*	Percent achieving 15% TBWL*
10.76%	10.8 kg	51.7%	52.6%	40.7%

*Reported as mean difference compared to placebo group

- Dose dependent response
- Potentially less weight loss observed in patients with diabetes

Semaglutide Safety

Discontinuation higher in semaglutide groups (6.4% vs. 3.1%)

• Reasons: GI adverse effects

Higher SAE in semaglutide groups

- Abdominal pain, vomiting, pancreatitis, cholecystitis, cholelithiasis, gastroenteritis
- All event rates low overall

Acute pancreatitis < 0.002%


Clinical considerations for semaglutide

Two brand names approved for different indications with different injection devices

Washout period for pregnancy


Taper orders and refills/days supply

Semaglutide Injection – Ozempic®



Semaglutide injection – Wegovy®

- No visible needle
- Pressure activated
- Patients sometimes say they did not get full dose
- One pen is one dose, no way to adjust



Apply pressure

ORAL SEMAGLUTIDE: RYBELSUS®



Did report CV benefit, but only when pooled results with injectable



Administration: morning on empty stomach with 4 oz of water at least 30 minutes before food, drink, or other medicines

OTHER GLP-1 AGONISTS

Dulaglutide (Trulicity[®]) Approved for diabetes only

Once weekly dosing with autoinjector

Exenatide (Bydureon®) Daily versus weekly

SWITCHING BETWEEN GLP-1 AGONISTS

- Consider reason for switch:
 - GI side effects → STOP agent, wait for side effects to resolve and start with lowest available dose
 - Other → start new agent when next dose due; start equivalent or lower dose
- Monitor for side effects and efficacy

	Agent	Frequency			Equivalent D	ose (mg)		
	Liraglutide	Weekly	0.6	1.2	1.8	2.4*	3*	
	Semaglutide	Weekly		0.25	0.5	1	1.7*	2.4*
	Oral semaglutide	Daily	3	7	14			
	Exenatide	Weekly			2			
	Dulaglutide	Weekly		0.75	1.5	3*	4.5*	
Diahet	es Ther 12, 943–954 (2021).	VVEEKIY		0.75	1.5	3	4.0	

GLP-1 and GIP Dual Agonist

TIRZEPATIDE (MOUNJARO®, ZEPBOUND®)

TIRZEPATIDE

- Mechanism:
 - Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist
 - GIP intestinal hormone, stimulates glucose dependent insulin secretion postprandially, stimulated glucagon secretion in periods of eu- and hypoglycemia
- FDA indication: Diabetes type 2; weight management, chronic
- Contraindications, cautions, side effects: same as GLP-1 agonists

Lexicomp. Tirzepatide. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp

Tirzepatide Literature – weight loss

- n=3964 in treatment group
- Mean age: 44.9 years
- Predominantly female
- Lifestyle: calorie deficit

Mean Starting Weight	Mean Starting BMI	Mean Starting Waist Circumference	Comorbidities	Follow Up Duration
10.8.8 kg	38 kg/m ²	114.1 cm	Excluded DM	72 weeks

N Engl J Med 2022; 387:205-216.

Tirzepatide Outcomes

Dose	% TBWL*	Percent achieving 5% TBWL*	Percent achieving 10% TBWL*	Percent achieving 20% TBWL*
5 mg	11.9%	50%	49.7%	26.9%
10 mg	16.4%	54%	59.3%	47%
15 mg	17.8%	56%	64.7%	54%

*Reported as mean difference compared to placebo group

• Improvements in all prespecified cardiometabolic measures with tirzepatide

N Engl J Med 2022; 387:205-216.

Tirzepatide Safety

Discontinuation higher in tirzepatide groups (4.3-7.1% vs.2.6%)

- Reasons: mild-moderate GI adverse effects
- No difference in SAE

Nausea and diarrhea more common in tirzepatide group

Acute pancreatitis: 0.2% (similar to placebo group)

N Engl J Med 2022; 387:205-216.

DIETARY TIPS FOR GLP-1 AGONISTS

Smaller portions. Start with half size (may help to use smaller plate) Eat protein to prevent loss of muscle mass (¼ of plate each meal and with snacks) Eat produce for nutrients (non-starchy veggies for ½ of plate each meal plus fruit)

Add extra fiber through whole grains and starchy veggies to reduce constipation Keep fat portions small and from heart healthy, unsaturated sources (olive oil, nuts, seeds, avocado)

Greasy, fried foods NOT well tolerated

Drink plenty of fluids (mostly water) separately from eating to not interfere with food intake

Eat regularly - 3 small meals per day plus healthy snack as needed

Let's Review

44

What is the primary mechanism of action of SGLT-2 inhibitors in type 2 diabetes?

- A. Increasing insulin secretion
- B. Inhibiting glucose reabsorption in the kidneys
- C. Slowing gastric emptying
- D. Blocking carbohydrate absorption in the intestines

Which class of medications has shown cardiovascular benefits in type 2 diabetes patients?

A. Insulins

B. Sulfonylureas

C. GLP-1 receptor agonists

D. DPP-4 inhibitors

A patient is prescribed liraglutide. What is a common side effect they might experience?

A. Hypoglycemia

B. GI disturbances (nausea, vomiting)

C. Increased appetite

D. Weight gain

Which of the following is a recommended dietary adjustment for patients using GLP-1 receptor agonists?

- A. Eat larger meals to prevent nausea
- B. Drink plenty of fluids separately from meals
- C. Increase fat intake for better absorption
- D. Avoid fiber to reduce GI side effects

Which of the following statements is TRUE regarding the oral formulation of semaglutide (Rybelsus®)?

A. It must be taken with food to enhance absorption

B. It is less effective than injectable semaglutide in reducing A1C

C. It should be taken on an empty stomach with water at least 30 minutes before eating

D. It has no cardiovascular benefit compared to injectable forms

Diabetes Management Approaches

Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes

Obesity is a chronic disease with metabolic, physical, and psychosocial complications.

Weight management can delay the progression from prediabetes to type 2 diabetes and is beneficial in treating type 2 diabetes.

ASSESSMENT AND MONITORING

Use	Use person-centered, nonjudgmental language.	
Measure	Measure BMI and other body fat distribution metrics.	
Monitor	Monitor obesity-related measurements annually or more frequently during active weight management.	

TREATMENT GOALS



WEIGHT MANAGEMENT SHOULD BE A

PRIMARY GOAL ALONG WITH GLYCEMIC MANAGEMENT.

AIM FOR 3-7% WEIGHT LOSS TO IMPROVE GLYCEMIA AND CARDIOVASCULAR RISK FACTORS.

10% WEIGHT LOSS CAN LEAD TO DISEASE-MODIFYING EFFECTS AND POSSIBLE DIABETES REMISSION.

TREATMENT APPROACHES

Lifestyle and Nutritional Therapy: Individualized based on medical history, preferences, and motivation.

- Create an energy deficit of 500-750 kcal/day.
- Individualize nutrition plans based on preferences and needs.
- Long-term weight maintenance programs with ongoing support and monitoring.

Metabolic Surgery: For significant weight loss and glycemic improvement.

- Consider for individuals with BMI \geq 30 kg/m² (\geq 27.5 kg/m² for Asian Americans).
- Long-term medical and behavioral support is essential post-surgery.

Pharmacologic Agents: Consider medications with beneficial effects on weight.

PHARMACOTHERAPY

Minimize medications associated with weight gain. Prioritize glucose-lowering medications with beneficial effects on weight. Consider weight management pharmacotherapy along with lifestyle changes. GLP-1 receptor agonists and dual GIP and GLP-1 receptor agonists are preferred.

COMMON MEDICATIONS ASSOCIATED WITH WEIGHT GAIN

Types of Medication	Medications or Classes	
Antidepressants	TCAs, phenelzine, paroxetine, mirtazapine,	
Mood stabilizers	Lithium, chlorpromazine, clozapine, olanzapine, paliperidone, quetiapine, risperidone	
Cardiovascular	CCB, atenolol, metoprolol, propranolol	
Diabetes agents	Insulin, sulfonylureas, TZDs	
Hormones	Estrogen, steroids	
Hypnotics	Diphenhydramine	
Antiepileptics	Carbamazepine, gabapentin, pregabalin, valproate	
	Am Fam Physician. 2016;94(5):361-8.	

COMMON MEDICATIONS THAT ARE WEIGHT NEUTRAL


Types of Medication	Medications or Classes	
Antidepressants	Citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine	
Antipsychotics	Aripiprazole, haloperidol, ziprasidone	
Cardiovascular	ACE inhibitors	
Diabetes agents	DPP4 inhibitors	
Hypnotics	Benzodiazepines, trazodone	
Mood stabilizers/ antiepileptics	Oxcarbazepine, lamotrigine, levetiracetam, phenytoin	
	Am Fam Physician. 2016;94(5):361-8.	5

COMMON MEDICATIONS ASSOCIATED WITH WEIGHT LOSS

Types of Medication	Medications or Classes
Antidepressants	Bupropion
Diabetes agents	Alpha-glucosidase inhibitors, GLP1 agonists, GLP-1/GIP agonists, metformin, pramlintide, SGLT-2 inhibitors
Hormones	Progestins, testosterone
Antiepileptics	Felbamate, topiramate, zonisamide
Stimulants	Amphetamines, methylphenidate, phentermine

ALTERNATIVE MEDICATIONS IN DIABETES





PHARMACIST'S ROLE IN PHARMACOTHERAPY

- Educate patients on the use and benefits of weight management medications.
- Monitor for side effects and interactions with other medications.
- Adjust medication regimens based on patient response and preferences.

Cardiovascular Disease and Risk Management in Diabetes

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in people with diabetes.

Diabetes increases the risk of ASCVD, with common coexisting conditions like hypertension, hyperlipidemia, and obesity.

American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S336. Available from: https://diabetesjournals.org/care/issue/48/Supplement_1. Accessed 2025 Mar 3.

61

LIPID MANAGEMENT

- High-intensity statin therapy is recommended for individuals aged 40-75 years with diabetes and high cardiovascular risk.
- Target LDL cholesterol reduction by ≥50% of baseline and aim for LDL <70 mg/dL (<1.8 mmol/L).

ANTIPLATELET THERAPY

- Aspirin (75-162 mg/day) is recommended for individuals with diabetes and a history of ASCVD.
 (SECONDARY PREVENTION)
- Consider aspirin therapy for primary prevention in individuals at high cardiovascular risk after discussing potential benefits and risks.

HEART FAILURE MANAGEMENT

- Heart failure is a major cause of morbidity and mortality in people with diabetes.
- Use SGLT2 inhibitors to reduce the risk of heart failure hospitalization.

Chronic Kidney Disease and Risk Management in Diabetes

Chronic Kidney Disease (CKD) is a common complication in diabetes, affecting 20-40% of people with diabetes.

CKD increases the risk of cardiovascular disease and healthcare costs

SCREENING RECOMMENDATIONS

- Assess kidney function (urine albumin creatinine ratio (UACR) and eGFR) in type 1 diabetes (duration ≥5 years) and all type 2 diabetes patients.
- Monitor urinary albumin and eGFR 1-4 times per year in established CKD.

PHARMACOTHERAPY TO LOWER ALBUMINURIA

ACE Inhibitors or ARBs

- Diabetes + hypertension + moderately increased albuminuria (UACR 30–299 mg/g creatinine)
- Strongly recommended for those with severely increased albuminuria (UACR ≥300 mg/g creatinine) and/or eGFR <60 mL/min/1.73 m²
- Monitor serum creatinine and potassium
- SGLT2 Inhibitors
 - Reduce CKD progression and cardiovascular events
 - With eGFR ≥ 20 mL/min/1.73 m²
- GLP-1 Receptor Agonists
 - Reduce cardiovascular risk and kidney disease

Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs)

- Reduce cardiovascular events and CKD progression
- eGFR ≥25 mL/min/1.73 m²
- Monitor potassium

ADDITIONAL CONSIDERATIONS TO LOWER ALBUMINURIA


Effective glucose management

Optimize Blood Pressure Management


- Blood pressure target of <130/80 mmHg
- **Dietary Protein Intake**
 - non-dialysis stage G3 or higher CKD \rightarrow 0.8 g/kg body weight/day
 - Dialysis \rightarrow 1.0–1.2 g/kg/day


Lifestyle Modifications

- Smoking cessation
- Weight loss
- Changes in eating patterns (e.g., decreased salt and protein intake)









Let's Review

73

What is a key potential benefit of GLP-1 receptor agonists in patients with type 2 diabetes beyond glycemic control?

- A. Increased insulin resistance
- B. Weight gain
- c. Cardiovascular risk reduction
- D. Increased hepatic glucose production

Which class of diabetes medications has been shown to provide cardiovascular benefits, including reduced risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease?

- A. Sulfonylureas
- B. Dipeptidyl peptidase-4 (DPP-4) inhibitors
- c. Sodium-glucose cotransporter-2 (SGLT2) inhibitors
- D. Insulin

What class of medication has NOT been shown to help reduce albuminuria?

- A. Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs)
- B. ACE Inhibitors
- c. Sulfonylureas
- D. GLP-1 Receptor Agonists
- E. GLP-1 Receptor Agonists

Continuous Glucose Monitors (CGMs)



WHAT ARE CGMS?

- Thin filament inserted under skin that connects to a small sensor and wirelessly transmits to a reader/smartphone
- Personal (patient monitored)
 - Can upload device to computer
 - Can remotely transmit data to provider practice
- Professional (provider monitored)
- Real time or intermittent scanning

Select CGM brands

- Abbott Freestyle Libre®
- Dexcom®
- Eversense®
- Guardian®

Common Personal Use CGMs

	Abbott Freestyle Libre 2 (plus) ®	Abbott Freestyle Libre 3 (plus) ®	
Components	 Disposable sensor/transmitter Reader for data display/storage 		
Maximum wear time	14(15) days		
Approved sites	Back of upper arm		
Warm up time	1 hour		
Downloading Software	LibreView		
FDA approved for Medication Adjustment	Yes		
Alarms for highs/lows	Yes		
Interfering substances	Ascorbic acid (>500 mg)		
Water resistance	3 feet/30 minutes		
FDA approved ages	<u>></u> 4		
Sensor size	2 stacked quarters	2 stacked pennies	
Data capture	Intermittent scanning required	Every minute, no scanning	

Abbott. FreeStyle [Internet]. Abbott; [cited 2025 Mar 2]. Available from: https://www.freestyle.abbott/us-en/home.html

Common Personal Use CGMs - Dexcom

	Dexcom G6 ®	Dexcom G7 ®	
Components	Disposable sensor Reusable transmitter Reader for data display/sto	Disposable sensor/transmitter Reader for data display/storage rage	
Maximum wear time	10 days	10 days*> 15 days	
Approved sites	Lower abdomen	Back of upper arm Upper buttocks (children)	
Warm up time	2 hours 30 minutes		
Downloading Software	Dexcom Clarity, Glooko, Tidepool		
FDA approved for Medication Adjustment	Yes		
Alarms for highs/lows	Yes		
Interfering substances	Hydroxyurea, acetaminophen (≥1 gram)		
Water resistance	8 feet/24 hours		
FDA approved ages	≥2 years		
Sensor size	oval size of 2 quarters	2 stacked pennies	
Data capture om. Dexcom G7 [Internet]. Dexcom; [cited 2025 Mar 2]. Available fro	Every 5 minutes (no scanning)		

Dexcom. Dexcom G7 [Internet]. Dexcom; [cited 2025 Mar 2]. Available from: https://uk.provider.dexcom.com/products/dexcom-g7

Who may benefit?

BASAL INSULIN USE AND CGM

Design	Multicenter, randomized, parallel group
Intervention	CGM or traditional blood glucose meter (BGM)
Primary Outcome	HbA1c
Key Secondary Outcomes	 CGM-measured time in target glucose range (70-180 mg/dL) Time with glucose > 250 mg/dL Mean glucose level
Population	 Adults with type 2 diabetes Receiving care from PCP 1-2 daily injections of long or intermediate acting basal insulin without prandial insulin With or without noninsulin medications
	IAMA_2021.325(22).2262-2272

JAMA. ZUZI, SZS(ZZ). ZZOZ-ZZ/Z.

BASAL INSULIN USE AND CGM - RESULTS

	CGM (n=116)	BGM (n=59)	P value
Change in HbA1c (%)	-1.1%	-0.6%	0.02
Percent CGM-measured time in target range (70-180 mg/dL)	+19%	+3%	<0.001
Percent time with glucose > 250 mg/dL	-14%	+2%	<0.001
Mean glucose level (mg/dL)	-30	0	<0.001

How much do CGMs cost?

CASH

- Abbott Freestyle Libre 3: \$140-170/month with GoodRx coupon (cost for 2 boxes, one sensor each)
- Dexcom G7: \$170-190/month with GoodRx coupon (cost for 3 boxes, one sensor each)

INSURANCE COVERAGE: MEDICARE

- Requires diagnosis of diabetes
- As of 2021, no longer requires patients to check blood glucose 4 times per day
- MUST have a daily insulin regimen (1 injection per day) OR have a history of documented problematic hypoglycemia
- Have been trained (or had caregiver trained) to use a continuous glucose monitor
- Provider visits every 6 months
- Covered as durable medical equipment in many plans

Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): Glucose Monitors (L33822) [Internet]. Baltimore (MD): CMS; [cited 2025 Mar 2]. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822

INSURANCE COVERAGE: WV MEDICAID

REQUIRES 3+ daily insulin administrations

6 months of adherence based on fill history

INSURANCE COVERAGE: OH MEDICAID

All patients with diagnosis of diabetes (2023)

INSURANCE COVERAGE: COMMERCIAL

- Variable
- May or may not require prior authorization
- WVU Employee Health Plan and Highmark covered with prior authorization

OTC Options

- Stelo[®] (Dexcom)
 - Subscriptions available for discount
- Lingo® (Abbott)
 - Subscription based
 - Sensors + coaching
- FSA/HSA eligible
- Targeted for patients without diabetes

Key Counseling Points

Application

Alerts

Adhesive

Irritation


Water

Replacements

Key Standardized Metrics


Time in Range	• Fasting AND post-prandial while avoiding hypoglycemia (70-180)
Number of Days Worn	• 14+ recommended
Percent of Time Active	 >70% recommended
Mean Glucose	 based on selected date range
Glucose Management Indicator (GMI)	• Estimate of HbA1c
Coefficient of Variation	• ≤ 36% recommended
Ambulatory Glucose Profile (AGP)	• Summary of glucose values with mean and percentiles as one day

TIME IN RANGE




Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care [Internet]. 2019 Aug;42(8):1593-1603. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6973648/

AMBULATORY GLUCOSE PROFILE EXAMPLE 1



AMBULATORY GLUCOSE PROFILE EXAMPLE 2




Reports


GLUCOSE STATISTICS AND TA	RGETS	TIME IN	RANGES	
June 30, 2021 - July 13, 2021	14 Days			
% Time CGM is Active	75%		Very High >250 mg/dL	17% (4h 5min)
Ranges And Targets For	Type 1 or Type 2 Diabetes			
Glucose Ranges	Targets % of Readings (Time/Day)	250		
Target Range 70-180 mg/dL	Greater than 70% (16h 48min)		High 181 - 250 mg/dL	40% (9h 36min)
Below 70 mg/dL	Less than 4% (58min)			
Below 54 mg/dL	Less than 1% (14min)	180		
Above 180 mg/dL	Less than 25% (6h)	180		
Above 250 mg/dL	Less than 5% (1h 12min)		Towned Downey	400/
Each 5% increase in time in range (70-180 mg	g/dL) is clinically beneficial.		Target Range 70 - 180 mg/dL	43% (10h 19min)
Average Glucose	197 mg/dL	70	LOW 54 - 69 mg/dL	0% (0min)
Glucose Management Indicator (GMI) 8.0%	54		0% (0min)
Glucose Variability	24.5%			
Defined as percent coefficient of variation (%	%CV); target ≤36%			

Real World Application

67 yof taking metformin 1000 mg BID, dapagliflozin 10 mg daily, insulin glargine 50 units nightly, insulin lispro 22 units TIDac

"I'm afraid to take my insulin"






July 12, 2021 - July 25, 2021 % Time CGM is Active	14 Days 58%
Ranges And Targets For	Type 1 or Type 2 Diabete
Glucose Ranges Target Range 70-180 mg/dL	Targets % of Readings (Time/Day) Greater than 70% (16h 48min)
Below 70 mg/dL	Less than 4% (58min)
Below 54 mg/dL	Less than 1% (14min)
Above 180 mg/dL	Less than 25% (6h)
Above 250 mg/dL	Less than 5% (1h 12min)
Each 5% increase in time in range (70-18	0 mg/dL) is clinically beneficial.
Average Glucose	179 mg/dL
Glucose Management Indicato	or (GMI) 7.6%
Glucose Variability Defined as percent coefficient of variatic	30.5% on (%CV); target ≤36%

TIME IN RANGES

	Very High >250 mg/dL	12% (2h 53min)
250	High 181-250 mg/dL	30% (7h 12min)
180		30 % (/n i2min)
	Target Range 70 - 180 mg/dL	58% (13h 55min)
70 54	Low 54 - 69 mg/dL	0% (0min)
	Very Low <54 mg/dL	0% (0min)

- Type 1 diabetes
- Insulin glargine 48 units nightly
- Insulin aspart 8 units TIDac



Abbott Diabetes Care. LibreView glucose report [Internet]. Alameda (CA): Abbott; 2025 Mar 2 [cited 2025 Mar 2]. Available from: https://www.libreview.com

Let's Review

102

Which of the following is a benefit of continuous glucose monitoring (CGM)?

- A. Eliminates the need for insulin in type 1 diabetes
- B. Provides real-time glucose data for better management
- C. Cures type 2 diabetes
- D. Replaces the need for HbA1c testing

What is a key requirement for Medicare coverage of CGM?

A. The patient must be using insulin or have hypoglycemia

- B. The patient must check blood glucose 4 times daily
- C. The patient must have type 1 diabetes
- D. The patient must be over 65 years old

Take Home Points

- SGLT-2 inhibitors and GLP-1 agonists provide multiple benefits beyond glucose lowering effects.
- Diabetes management should include a comprehensive approach, including considerations for weight management, cardiovascular health, and kidney disease.
- CGMs are becoming more accessible and may help patients be more aware of their glycemic control and lower HbA1c without additional therapies being needed
- CGM reports can be used to tailor therapy to individual patients.
- Pharmacists are positioned to help manage diabetes in conjunction with the healthcare team.

References

- American Diabetes Association. Standards of medical care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S336. Available from: https://diabetesjournals.org/care/issue/48/Supplement_1. Accessed 2025 Mar 3.
- Lexicomp. Lexi-Drugs. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; [updated 2025 Mar 03; cited 2025 Mar 03]. Available from: https://www.wolterskluwer.com/en/solutions/lexicomp
- Davies, M., D'Alessio, D. A., Fradkin, J., Garratt, C. J., Holman, R. R., Kahn, S. E., ... & Marso, S. P. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). The New England Journal of Medicine, 375(4), 311–322. <u>https://doi.org/10.1056/NEJMoa1603827</u>
- Erlandson M, Ivey LC, Seikel K. Update on office-based strategies for the management of obesity. Am Fam Physician. 2016;94(5):361-368.
- American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S207-S238. doi:10.2337/dc25-S010.
- American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S239-S253. doi:10.2337/dc25-S011.
- Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021 Jun 8;325(22):2262-2272. doi: 10.1001/jama.2021.7444.
- Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care [Internet]. 2019 Aug;42(8):1593-1603. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6973648/
- Dexcom. Dexcom G7 [Internet]. Dexcom; [cited 2025 Mar 2]. Available from: https://uk.provider.dexcom.com/products/dexcom-g7
- Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): Glucose Monitors (L33822) [Internet]. Baltimore (MD): CMS; [cited 2025 Mar 2]. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822
- Abbott Diabetes Care. LibreView glucose report [Internet]. Alameda (CA): Abbott; 2025 Mar 2 [cited 2025 Mar 2]. Available from: https://www.libreview.com

Questions?

107

CE Evaluation Access Code

Capital Letters, No spaces, complete by March 16, 2025

Note: CE credit will be reported to NABP CPE Monitor within 4-6 weeks

How sweet it is: Modern treatment approaches for type II diabetes

ANGELA L. GOODHART, PHARMD, BCACP ASSISTANT PROFESSOR OF CLINICAL PHARMACY AND FAMILY MEDICINE WEST VIRGINIA UNIVERSITY ANGELA.GOODHART@HSC.WVU.EDU